CMN Intelligence has released the CMN Clinical Trials Q2 2026 Global Report, based on data from the CRISPR Medicine News Global Clinical Trials...
A gene-edited pig kidney kept a patient with end-stage kidney disease dialysis-free for 271 days, then failed and was removed without leaving the...
The US FDA has accepted Intellia Therapeutics’ application for lonvoguran ziclumeran (lonvo-z, formerly NTLA-2002) and granted the in vivo CRISPR-Cas...
A single intravenous dose of the CRISPR-Cas9 therapy CTX310 – developed by CRISPR Therapeutics – held circulating ANGPTL3, triglycerides and LDL...
US regulators have granted RMAT and Fast Track designations to Allogene’s TALEN-edited, allogeneic CD19 CAR T-cell therapy cema-cel for first-line...
Copenhagen-based SNIPR reports today that an experimental CRISPR-armed phage therapy was associated with a remarkable clinical response in a kidney...
Three boys with Duchenne muscular dystrophy retained broadly stable motor function one year after receiving GEN6050X, an experimental base-editing and...
The first approved CRISPR medicine has now shown similarly strong results in children as young as five years old with sickle cell disease and...
